标题
Targeted therapy in the treatment of uterine serous carcinoma
作者
关键词
-
出版物
PHARMACOGENOMICS
Volume 16, Issue 2, Pages 97-99
出版商
Future Medicine Ltd
发表日期
2015-01-23
DOI
10.2217/pgs.14.176
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
- (2014) C L Schwab et al. BRITISH JOURNAL OF CANCER
- Dual HER2 Targeting Impedes Growth of HER2 Gene-Amplified Uterine Serous Carcinoma Xenografts
- (2014) J. W. Groeneweg et al. CLINICAL CANCER RESEARCH
- Neratinib shows efficacy in the treatment of HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Carlton L. Schwab et al. GYNECOLOGIC ONCOLOGY
- Taselisib, a selective inhibitor of PIK3CA, is highly effective on PIK3CA-mutated and HER2/neu amplified uterine serous carcinoma in vitro and in vivo
- (2014) Salvatore Lopez et al. GYNECOLOGIC ONCOLOGY
- T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
- (2014) Diana P. English et al. Cancer Medicine
- Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2)
- (2013) Diana P. English et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor
- (2013) Diana P. English et al. GYNECOLOGIC ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice
- (2013) Natalia Buza et al. MODERN PATHOLOGY
- Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma
- (2013) S. Zhao et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
- (2011) P Todeschini et al. BRITISH JOURNAL OF CANCER
- Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer
- (2011) Karim S El-Sahwi et al. Expert Review of Anticancer Therapy
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
- (2009) Gini F. Fleming et al. GYNECOLOGIC ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started